Professor Neil Poulter

Vallejo-Vaz AJ, Bray S, Villa G, Brandts J, Kiru G, Murphy J, Banach M, De Servi S, Gaita D, Gouni-Berthold I, Hovingh GK, Jozwiak JJ, Jukema JW, Kiss RG, Kownator S, Iversen HK, Maher V, Masana L, Parkhomenko A, Peeters A, Clifford P, Raslova K, Siostrzonek P, Romeo S, Tousoulis D, Vlachopoulos C, Vrablik M, Catapano AL, Poulter NR, Ray KKet al., 2023, Implications of ACC/AHA Versus ESC/EAS LDL-C recommendations for residual risk reduction in ASCVD: a simulation study from DA VINCI, Cardiovascular Drugs and Therapy, Vol: 37, Pages: 941-953, ISSN: 0920-3206

PurposeLow-density lipoprotein cholesterol (LDL-C) recommendations differ between the 2018 American College of Cardiology/American Heart Association (ACC/AHA) and 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines for patients with atherosclerotic cardiovascular disease (ASCVD) (< 70 vs. < 55 mg/dl, respectively). In the DA VINCI study, residual cardiovascular risk was predicted in ASCVD patients. The extent to which relative and absolute risk might be lowered by achieving ACC/AHA versus ESC/EAS LDL-C recommended approaches was simulated.MethodsDA VINCI was a cross-sectional observational study of patients prescribed lipid-lowering therapy (LLT) across 18 European countries. Ten-year cardiovascular risk (CVR) was predicted among ASCVD patients receiving stabilized LLT. For patients with LDL-C ≥ 70 mg/dl, the absolute LDL-C reduction required to achieve an LDL-C of < 70 or < 55 mg/dl (LDL-C of 69 or 54 mg/dl, respectively) was calculated. Relative and absolute risk reductions (RRRs and ARRs) were simulated.ResultsOf the 2039 patients, 61% did not achieve LDL-C < 70 mg/dl. For patients with LDL-C ≥ 70 mg/dl, median (interquartile range) baseline LDL-C and 10-year CVR were 93 (81–115) mg/dl and 32% (25–43%), respectively. Median LDL-C reductions of 24 (12–46) and 39 (27–91) mg/dl were needed to achieve an LDL-C of 69 and 54 mg/dl, respectively. Attaining ACC/AHA or ESC/EAS goals resulted in simulated RRRs of 14% (7–25%) and 22% (15–32%), respectively, and ARRs of 4% (2–7%) and 6% (4–9%), respectively.ConclusionIn ASCVD patients, achieving ESC/EAS LDL-C goals could result in a 2% additional ARR over 10 years versus the ACC/AHA approach.

• Abstract
• Publisher Web Link
• Author Web Link
• Open Access Link
• Cite

Brandts J, Bray S, Villa G, Catapano AL, Poulter NR, Vallejo-Vaz AJ, Ray KK, DA VSGet al., 2023, Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI, LANCET REGIONAL HEALTH-EUROPE, Vol: 31, ISSN: 2666-7762

• Author Web Link
• Cite
• Citations: 2

McGuire DK, Busui RP, Deanfield J, Inzucchi SE, Mann JFE, Marx N, Mulvagh SL, Poulter N, Engelmann MDM, Hovingh GK, Ripa MS, Gislum M, Brown-Frandsen K, Buse JBet al., 2023, Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial., Diabetes Obes Metab, Vol: 25, Pages: 1932-1941

AIM: To describe the design of the SOUL trial (Semaglutide cardiOvascular oUtcomes triaL) and the baseline clinical data of its participants. MATERIALS AND METHODS: In SOUL, the effects of oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist, on the risk of cardiovascular (CV) events in individuals with type 2 diabetes and established atherosclerotic CV disease (ASCVD) and/or chronic kidney disease (CKD) will be assessed. SOUL is a randomized, double-blind, parallel-group, placebo-controlled CV outcomes trial comparing oral semaglutide (14 mg once daily) with placebo, both in addition to standard of care, in individuals aged ≥50 years with type 2 diabetes and evidence of ASCVD (coronary artery disease [CAD], cerebrovascular disease, symptomatic peripheral arterial disease [PAD]) and/or CKD (estimated glomerular filtration rate <60 mL/min/1.73 m2 ). The primary outcome is time from randomization to first occurrence of a major adverse CV event (MACE; a composite of CV death, nonfatal myocardial infarction or nonfatal stroke). This event-driven trial will continue until 1225 first adjudication-confirmed MACEs have occurred. Enrolment has been completed. RESULTS: Overall, 9650 participants were enrolled between June 17, 2019 and March 24, 2021 (men 71.1%, White ethnicity 68.9%, mean age 66.1 years, diabetes duration 15.4 years, body mass index 31.1 kg/m2 , glycated haemoglobin 63.5 mmol/mol [8.0%]). The most frequently used antihyperglycaemic medications at baseline were metformin (75.7%), insulin and insulin analogues (50.5%), sulphonylureas (29.1%), sodium-glucose cotransporter-2 inhibitors (26.7%) and dipeptidyl peptidase-4 inhibitors (23.0%). At randomization, 70.7% of participants had CAD, 42.3% had CKD, 21.1% had cerebrovascular disease and 15.7% had symptomatic PAD (categories not mutually exclusive). Prevalent heart failure was reported in 23.0% of participants. CONCLUSION:

• Abstract
• Author Web Link
• Cite

Beaney T, Wang W, Schlaich MP, Schutte AE, Stergiou GS, Alcocer L, Alsaid J, Diaz AB, Hernandez-Hernandez R, Ishaq M, Jozwiak J, Khan N, Kiru G, McCardle H, Odili AN, Pyun WB, Romero CA, Wang J, Poulter NR, MMM Investigatorset al., 2023, Global blood pressure screening during the COVID-19 pandemic: results from the May Measurement Month 2021 campaign, Journal of Hypertension, Vol: 41, Pages: 1446-1455, ISSN: 0263-6352

BACKGROUND: Raised blood pressure (BP) remains the biggest risk factor contributing to the global burden of disease and mortality, despite the COVID-19 pandemic. May Measurement Month (MMM), an annual global screening campaign aims to highlight the importance of BP measurement by evaluating global awareness, treatment and control rates among adults with hypertension. In 2021, we assessed the global burden of these rates during the COVID-19 pandemic. METHODS: Screening sites were set up in 54 countries between May and November 2021 and screenees were recruited by convenience sampling. Three sitting BPs were measured, and a questionnaire completed including demographic, lifestyle and clinical data. Hypertension was defined as a systolic BP at least 140 mmHg and/or a diastolic BP at least 90 mmHg (using the mean of the second and third readings) or taking antihypertensive medication. Multiple imputation was used to impute the average BP when readings were missing. RESULTS: Of the 642 057 screenees, 225 882 (35.2%) were classified as hypertensive, of whom 56.8% were aware, and 50.3% were on antihypertensive medication. Of those on treatment, 53.9% had controlled BP (<140/90 mmHg). Awareness, treatment and control rates were lower than those reported in MMM campaigns before the COVID-19 pandemic. Minimal changes were apparent among those testing positive for, or being vaccinated against COVID-19. Of those on antihypertensive medication, 94.7% reported no change in their treatment because of the COVID-19 pandemic. CONCLUSION: The high yield of untreated or inadequately treated hypertension in MMM 2021 confirms the need for systematic BP screening where it does not currently exist.

• Abstract
• Publisher Web Link
• Author Web Link
• Open Access Link
• Cite

Graham SE, Clarke SL, Wu K-HH, Kanoni S, Zajac GJM, Ramdas S, Surakka I, Ntalla I, Vedantam S, Winkler TW, Locke AE, Marouli E, Hwang MY, Han S, Narita A, Choudhury A, Bentley AR, Ekoru K, Verma A, Trivedi B, Martin HC, Hunt KA, Hui Q, Klarin D, Zhu X, Thorleifsson G, Helgadottir A, Gudbjartsson DF, Holm H, Olafsson I, Akiyama M, Sakaue S, Terao C, Kanai M, Zhou W, Brumpton BM, Rasheed H, Ruotsalainen SE, Havulinna AS, Veturi Y, Feng Q, Rosenthal EA, Lingren T, Pacheco JA, Pendergrass SA, Haessler J, Giulianini F, Bradford Y, Miller JE, Campbell A, Lin K, Millwood IY, Hindy G, Rasheed A, Faul JD, Zhao W, Weir DR, Turman C, Huang H, Graff M, Mahajan A, Brown MR, Zhang W, Yu K, Schmidt EM, Pandit A, Gustafsson S, Yin X, Luan J, Zhao J-H, Matsuda F, Jang H-M, Yoon K, Medina-Gomez C, Pitsillides A, Hottenga JJ, Willemsen G, Wood AR, Ji Y, Gao Z, Haworth S, Mitchell RE, Chai JF, Aadahl M, Yao J, Manichaikul A, Warren HR, Ramirez J, Bork-Jensen J, Karhus LL, Goel A, Sabater-Lleal M, Noordam R, Sidore C, Fiorillo E, McDaid AF, Marques-Vidal P, Wielscher M, Trompet S, Sattar N, Mollehave LT, Thuesen BH, Munz M, Zeng L, Huang J, Yang B, Poveda A, Kurbasic A, Lamina C, Forer L, Scholz M, Galesloot TE, Bradfield JP, Daw EW, Zmuda JM, Mitchell JS, Fuchsberger C, Christensen H, Brody JA, Feitosa MF, Wojczynski MK, Preuss M, Mangino M, Christofidou P, Verweij N, Benjamins JW, Engmann J, Kember RL, Slieker RC, Lo KS, Zilhao NR, Le P, Kleber ME, Delgado GE, Huo S, Ikeda DD, Iha H, Yang J, Liu J, Leonard HL, Marten J, Schmidt B, Arendt M, Smyth LJ, Canadas-Garre M, Wang C, Nakatochi M, Wong A, Hutri-Kahonen N, Sim X, Xia R, Huerta-Chagoya A, Fernandez-Lopez JC, Lyssenko V, Ahmed M, Jackson AU, Yousri NA, Irvin MR, Oldmeadow C, Kim H-N, Ryu S, Timmers PRHJ, Arbeeva L, Dorajoo R, Lange LA, Chai X, Prasad G, Lores-Motta L, Pauper M, Long J, Li X, Theusch E, Takeuchi F, Spracklen CN, Loukola A, Bollepalli S, Warner SC, Wang YX, Wei WB, Nutile T, Ruggiero D, Sung YJ, Hung Y-J, Chen S, Liet al., 2023, Author Correction: The power of genetic diversity in genome-wide association studies of lipids, Nature, Vol: 618, Pages: E19-E20, ISSN: 0028-0836

• Publisher Web Link
• Author Web Link
• Open Access Link
• Cite

Carnagarin R, Nolde JM, Yang J, Marques FZ, Picone DS, Lambert GW, Beaney T, Poulter NR, Schutte AE, Reid CM, Brockman D, Schlaich MPet al., 2023, Stagnating rates of blood pressure control in Australia: insights from opportunistic screening of 10 046 participants of the <i>May Measurement Month</i> campaigns, JOURNAL OF HYPERTENSION, Vol: 41, Pages: 632-637, ISSN: 0263-6352

• Author Web Link
• Cite

Schutte AE, Jafar TH, Poulter NR, Damasceno A, Khan NA, Nilsson PM, Alsaid J, Neupane D, Kario K, Beheiry H, Brouwers S, Burger D, Charchar FJ, Cho MC, Guzik TJ, Al-Saedi GFH, Ishaq M, Itoh H, Jones ESW, Khan T, Kokubo Y, Kotruchin P, Muxfeldt E, Odili A, Patil M, Ralapanawa U, Romero CA, Schlaich MP, Shehab A, Mooi CS, Steckelings UM, Stergiou G, Touyz RM, Unger T, Wainford RD, Wang J-G, Williams B, Wynne BM, Tomaszewski Met al., 2023, Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension, CARDIOVASCULAR RESEARCH, Vol: 119, Pages: 381-409, ISSN: 0008-6363

• Author Web Link
• Cite
• Citations: 9

Kanagaratnam P, McCready J, Tayebjee M, Shepherd E, Sasikaran T, Todd D, Johnson N, Kyriacou A, Hayat S, Hobson NA, Mann I, Balasubramaniam R, Whinnett Z, Earley M, Petkar S, Veasey R, Kirubakaran S, Coyle C, Kim M-Y, Lim PB, O'Neill J, Davies DW, Peters NS, Babalis D, Linton N, Falaschetti E, Tanner M, Shah J, Poulter Net al., 2023, Ablation versus anti-arrhythmic therapy for reducing all hospital episodes from recurrent atrial fibrillation: a prospective, randomized, multi-centre, open label trial, EP Europace, Vol: 25, Pages: 863-872, ISSN: 1099-5129

Aims:There is rising healthcare utilization related to the increasing incidence and prevalence of atrial fibrillation (AF) worldwide. Simplifying therapy and reducing hospital episodes would be a valuable development. The efficacy of a streamlined AF ablation approach was compared to drug therapy and a conventional catheter ablation technique for symptom control in paroxysmal AF.Methods and results:We recruited 321 patients with symptomatic paroxysmal AF to a prospective randomized, multi-centre, open label trial at 13 UK hospitals. Patients were randomized 1:1:1 to cryo-balloon ablation without electrical mapping with patients discharged same day [Ablation Versus Anti-arrhythmic Therapy for Reducing All Hospital Episodes from Recurrent (AVATAR) protocol]; optimization of drug therapy; or cryo-balloon ablation with confirmation of pulmonary vein isolation and overnight hospitalization. The primary endpoint was time to any hospital episode related to treatment for atrial arrhythmia. Secondary endpoints included complications of treatment and quality-of-life measures. The hazard ratio (HR) for a primary endpoint event occurring when comparing AVATAR protocol arm to drug therapy was 0.156 (95% CI, 0.097–0.250; P < 0.0001 by Cox regression). Twenty-three patients (21%) recorded an endpoint event in the AVATAR arm compared to 76 patients (74%) within the drug therapy arm. Comparing AVATAR and conventional ablation arms resulted in a non-significant HR of 1.173 (95% CI, 0.639–2.154; P = 0.61 by Cox regression) with 23 patients (21%) and 19 patients (18%), respectively, recording primary endpoint events (P = 0.61 by log-rank test).Conclusion:The AVATAR protocol was superior to drug therapy for avoiding hospital episodes related to AF treatment, but conventional cryoablation was not superior to the AVATAR protocol. This could have wide-ranging implications on how demand for AF symptom control is met.Trial registrationClinical Trials Registration: NCT02459574.

• Abstract
• Publisher Web Link
• Open Access Link
• Cite

Wang N, Harris K, Woodward M, Harrap S, Mancia G, Poulter N, Chalmers J, Rodgers Aet al., 2023, Clinical Utility of Short-Term Blood Pressure Measures to Inform Long-Term Blood Pressure Management, HYPERTENSION, Vol: 80, Pages: 608-617, ISSN: 0194-911X

• Author Web Link
• Cite
• Citations: 2

Kanoni S, Graham SE, Wang Y, Surakka I, Ramdas S, Zhu X, Clarke SL, Bhatti KF, Vedantam S, Winkler TW, Locke AE, Marouli E, Zajac GJM, Wu K-HH, Ntalla I, Hui Q, Klarin D, Hilliard AT, Wang Z, Xue C, Thorleifsson G, Helgadottir A, Gudbjartsson DF, Holm H, Olafsson I, Hwang MY, Han S, Akiyama M, Sakaue S, Terao C, Kanai M, Zhou W, Brumpton BM, Rasheed H, Havulinna AS, Veturi Y, Pacheco JA, Rosenthal EA, Lingren T, Feng Q, Kullo IJ, Narita A, Takayama J, Martin HC, Hunt KA, Trivedi B, Haessler J, Giulianini F, Bradford Y, Miller JE, Campbell A, Lin K, Millwood IY, Rasheed A, Hindy G, Faul JD, Zhao W, Weir DR, Turman C, Huang H, Graf M, Choudhury A, Sengupta D, Mahajan A, Brown MR, Zhang W, Yu K, Schmidt EM, Pandit A, Gustafsson S, Yin X, Luan J, Zhao J-H, Matsuda F, Jang H-M, Yoon K, Medina-Gomez C, Pitsillides A, Hottenga JJ, Wood AR, Ji Y, Gao Z, Haworth S, Yousri NA, Mitchell RE, Chai JF, Aadahl M, Bjerregaard AA, Yao J, Manichaikul A, Hwu C-M, Hung Y-J, Warren HR, Ramirez J, Bork-Jensen J, Karhus LL, Goel A, Sabater-Lleal M, Noordam R, Mauro P, Matteo F, McDaid AF, Marques-Vidal P, Wielscher M, Trompet S, Sattar N, Mollehave LT, Munz M, Zeng L, Huang J, Yang B, Poveda A, Kurbasic A, Lamina C, Forer L, Scholz M, Galesloot TE, Bradfeld JP, Ruotsalainen SE, Daw E, Zmuda JM, Mitchell JS, Fuchsberger C, Christensen H, Brody JA, Vazquez-Moreno M, Feitosa MF, Wojczynski MK, Wang Z, Preuss MH, Mangino M, Christofdou P, Verweij N, Benjamins JW, Engmann J, Tsao NL, Verma A, Slieker RC, Lo KS, Zilhao NR, Le P, Kleber ME, Delgado GE, Huo S, Ikeda DD, Iha H, Yang J, Liu J, Leonard HL, Marten J, Frank M, Schmidt B, Smyth LJ, Canadas-Garre M, Wang C, Nakatochi M, Wong A, Hutri-Kahonen N, Sim X, Xia R, Huerta-Chagoya A, Fernandez-Lopez JC, Lyssenko V, Nongmaithem SS, Bayyana S, Stringham HM, Irvin MR, Oldmeadow C, Kim H-N, Ryu S, Timmers PRHJ, Arbeeva L, Dorajoo R, Lange LA, Prasad G, Lores-Motta L, Pauper M, Long J, Li X, Theusch E, Takeuchi F, Spracklen CN, Loukola A, Bollepalliet al., 2022, Implicating genes, pleiotropy, and sexual dimorphism at blood lipid loci through multi-ancestry meta-analysis, Genome Biology, Vol: 23, ISSN: 1474-7596

BackgroundGenetic variants within nearly 1000 loci are known to contribute to modulation of blood lipid levels. However, the biological pathways underlying these associations are frequently unknown, limiting understanding of these findings and hindering downstream translational efforts such as drug target discovery.ResultsTo expand our understanding of the underlying biological pathways and mechanisms controlling blood lipid levels, we leverage a large multi-ancestry meta-analysis (N = 1,654,960) of blood lipids to prioritize putative causal genes for 2286 lipid associations using six gene prediction approaches. Using phenome-wide association (PheWAS) scans, we identify relationships of genetically predicted lipid levels to other diseases and conditions. We confirm known pleiotropic associations with cardiovascular phenotypes and determine novel associations, notably with cholelithiasis risk. We perform sex-stratified GWAS meta-analysis of lipid levels and show that 3–5% of autosomal lipid-associated loci demonstrate sex-biased effects. Finally, we report 21 novel lipid loci identified on the X chromosome. Many of the sex-biased autosomal and X chromosome lipid loci show pleiotropic associations with sex hormones, emphasizing the role of hormone regulation in lipid metabolism.ConclusionsTaken together, our findings provide insights into the biological mechanisms through which associated variants lead to altered lipid levels and potentially cardiovascular disease risk.

• Abstract
• Publisher Web Link
• Author Web Link
• Open Access Link
• Cite

Ojji DB, Cornelius V, Partington G, Francis V, Pandie S, Smythe W, Hickman N, Barasa F, Damasceno A, Dzudie A, Jones E, Ingabire PM, Mondo C, Ogah O, Ogola E, Sani MU, Shedul GL, Shedul G, Rayner B, Sliwa K, Poulter Net al., 2022, Effect of 3, 2-Drug Combinations of Antihypertensive Therapies on Blood Pressure Variability in Black African Patients: Secondary Analyses of the CREOLE Trial, HYPERTENSION, Vol: 79, Pages: 2593-2600, ISSN: 0194-911X

• Author Web Link
• Cite
• Citations: 1

Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb DJ, Ford I, Rorie DA, Guthrie G, Grieve JWK, Pigazzani F, Rothwell PM, Young R, McConnachie A, Struthers AD, Lang CC, MacDonald TMet al., 2022, Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial, LANCET, Vol: 400, Pages: 1417-1425, ISSN: 0140-6736

• Author Web Link
• Cite
• Citations: 39

Quintana FSW, Casasola MAV, Lopez ACO, de Leon ER, Alvarado HS, Wang W, Beaney T, Poulter NRet al., 2022, May Measurement Month 2017-2019: an analysis of blood pressure screening results from Guatemala<SUP> </SUP>, EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol: 24, Pages: F16-F18, ISSN: 1520-765X

• Author Web Link
• Cite

Houehanou C, Sonou A, Adjagba P, Dohou H, Hounkponou M, Kpoledji G, Saka D, Assogba G, Assani S, Wang W, Beaney T, Poulter NR, Codjo L, Houenassi MDet al., 2022, May Measurement Month 2018: an analysis of blood pressure screening results from Benin<SUP> </SUP>, EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol: 24, Pages: F9-F11, ISSN: 1520-765X

• Author Web Link
• Cite

Poulter NR, Borghi C, Damasceno A, Jafar TH, Khan NA, Kokubo Y, Nilsson PM, Prabhakaran D, Schlaich MP, Schutte AE, Stergiou GS, Unger T, Wang W, Beaney Tet al., 2022, May Measurement Month: results of 12 national blood pressure screening programmes between 2017 and 2019, EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol: 24, Pages: F1-F5, ISSN: 1520-765X

• Author Web Link
• Cite
• Citations: 1

Kowlessur S, Ori B, Heecharan J, Poulter NR, Wang W, Beaney Tet al., 2022, May Measurement Month 2017: an analysis of blood pressure screening results from Mauritius<SUP> </SUP>, EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol: 24, Pages: F25-F27, ISSN: 1520-765X

• Author Web Link
• Cite

Miglinas M, Sevcenko V, Racaite A, Zakauskiene U, Vickiene A, Migline V, Wang W, Beaney T, Poulter NR, Macioniene Eet al., 2022, May Measurement Month 2017-2019: an analysis of blood pressure screening results from Lithuania<SUP> </SUP>, EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol: 24, Pages: F22-F24, ISSN: 1520-765X

• Author Web Link
• Cite

Memon FS, Wang W, Beaney T, Bai K, Poulter NR, Ishaq Met al., 2022, May Measurement Month 2018: an analysis of blood pressure screening results from Pakistan<SUP> </SUP>, EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol: 24, Pages: F31-F33, ISSN: 1520-765X

• Author Web Link
• Cite

Toure A, Ismael OY, Souley K, Bonkano AS, Boubacar D, Ousseini M, Mossi D, Issoufou GI, Souna M, Bonkano O, Majid A, Douma H, Wang W, Beaney T, Poulter NRet al., 2022, May Measurement Month 2017-19: an analysis of blood pressure screening results from Niger<SUP> </SUP>, EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol: 24, Pages: F28-F30, ISSN: 1520-765X

• Author Web Link
• Cite

Mirrakhimov E, Zakirov U, Abilova S, Asanbaev A, Bektasheva E, Asanaliev N, Uulu YM, Alibaeva N, Neronova K, Kerimkulova A, Lunegova O, Altymysheva A, Wang W, Beaney T, Poulter NRet al., 2022, May Measurement Month 2019: analysis of blood pressure screening in Bishkek, Kyrgyzstan<SUP> </SUP>, EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol: 24, Pages: F19-F21, ISSN: 1520-765X

• Author Web Link
• Cite

Mishchenko LA, Kolesnik T, Khomazyuk TA, Sirenko YM, Fedorov S, Wang W, Beaney T, Poulter NR, Zelenenka L, Matova OO, Yevstigneeva Oet al., 2022, May Measurement Month 2017-2019: an analysis of blood pressure screening results from Ukraine<SUP> </SUP>, EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol: 24, Pages: F41-F44, ISSN: 1520-765X

• Author Web Link
• Cite

Glantschnig T, Koppelstaetter C, Zweiker D, Kolesnik E, Niederl E, Kraler E, Stoff I, Zweiker R, Weber T, Horn S, Weiss T, Wang W, Beaney T, Poulter NR, Perl Set al., 2022, May Measurement Month 2018-2019: an analysis of blood pressure screening results from Austria<SUP> </SUP>, EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol: 24, Pages: F6-F8, ISSN: 1520-765X

• Author Web Link
• Cite

Valdez-Tiburcio O, Gonzalez-Medina A, Valdez-Valoy L, Santillan-Pascual M, Baez-Noyer N, Diaz-Montero B, Wang W, Beaney T, Poulter NRet al., 2022, May Measurement Month 2017-2019: an analysis of blood pressure screening results from Dominican Republic<SUP> </SUP>, EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol: 24, Pages: F12-F15, ISSN: 1520-765X

• Author Web Link
• Cite

Ortellado J, Paniagua M, Wang W, Beaney T, Poulter NR, Gonzalez G, Castillo M, Aparicio R, Villamayor Aet al., 2022, May Measurement Month 2017-19: an analysis of blood pressure screening results from Paraguay<SUP> </SUP>, EUROPEAN HEART JOURNAL SUPPLEMENTS, Vol: 24, Pages: F34-F37, ISSN: 1520-765X

• Author Web Link
• Cite

Stergiou G, Brunstrom M, MacDonald T, Kyriakoulis KG, Bursztyn M, Khan N, Bakris G, Kollias A, Menti A, Muntner P, Orias M, Poulter N, Shimbo D, Williams B, Adeoye AM, Damasceno A, Korostovtseva L, Li Y, Muxfeldt E, Zhang Y, Mancia G, Kreutz R, Tomaszewski Met al., 2022, Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension, JOURNAL OF HYPERTENSION, Vol: 40, Pages: 1847-1858, ISSN: 0263-6352

• Author Web Link
• Cite
• Citations: 17

Wang N, Harris K, Hamet P, Harrap S, Mancia G, Poulter N, Williams B, Zoungas S, Woodward M, Chalmers J, Rodgers Aet al., 2022, Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients With Diabetes, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol: 80, Pages: 1147-1155, ISSN: 0735-1097

• Author Web Link
• Cite
• Citations: 4

Gnanenthiran SR, Borghi C, Burger D, Caramelli B, Charchar F, Chirinos JA, Cohen JB, Cremer A, Di Tanna GL, Duvignaud A, Freilich D, Gommans DHF, Gracia-Ramos AE, Murray TA, Pelorosso F, Poulter NR, Puskarich MA, Rizas KD, Rothlin R, Schlaich MP, Schreinlecher M, Steckelings UM, Sharma A, Stergiou GS, Tignanelli CJ, Tomaszewski M, Unger T, van Kimmenade RRJ, Wainford RD, Williams B, Rodgers A, Schutte AEet al., 2022, Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension, JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol: 11

• Author Web Link
• Cite
• Citations: 15

Ramdas S, Judd J, Graham SE, Kanoni S, Wang Y, Surakka I, Wenz B, Clarke SL, Chesi A, Wells A, Bhatti KF, Vedantam S, Winkler TW, Locke AE, Marouli E, Zajac GJM, Wu K-HH, Ntalla I, Hui Q, Klarin D, Hilliard AT, Wang Z, Xue C, Thorleifsson G, Helgadottir A, Gudbjartsson DF, Holm H, Olafsson I, Hwang MY, Han S, Akiyama M, Sakaue S, Terao C, Kanai M, Zhou W, Brumpton BM, Rasheed H, Havulinna AS, Veturi Y, Pacheco JA, Rosenthal EA, Lingren T, Feng Q, Kullo IJ, Narita A, Takayama J, Martin HC, Hunt KA, Trivedi B, Haessler J, Giulianini F, Bradford Y, Miller JE, Campbell A, Lin K, Millwood IY, Rasheed A, Hindy G, Faul JD, Zhao W, Weir DR, Turman C, Huang H, Graff M, Choudhury A, Sengupta D, Mahajan A, Brown MR, Zhang W, Yu K, Schmidt EM, Pandit A, Gustafsson S, Yin X, Luan J, Zhao J-H, Matsuda F, Jang H-M, Yoon K, Medina-Gomez C, Pitsillides A, Hottenga JJ, Wood AR, Ji Y, Gao Z, Haworth S, Mitchell RE, Chai JF, Aadahl M, Bjerregaard AA, Yao J, Manichaikul A, Lee W-J, Hsiung CA, Warren HR, Ramirez J, Bork-Jensen J, Karhus LL, Goel A, Sabater-Lleal M, Noordam R, Mauro P, Matteo F, McDaid AF, Marques-Vidal P, Wielscher M, Trompet S, Sattar N, Mollehave LT, Munz M, Zeng L, Huang J, Yang B, Poveda A, Kurbasic A, Schonherr S, Forer L, Scholz M, Galesloot TE, Bradfield JP, Ruotsalainen SE, Daw EW, Zmuda JM, Mitchell JS, Fuchsberger C, Christensen H, Brody JA, Le P, Feitosa MF, Wojczynski MK, Hemerich D, Preuss M, Mangino M, Christofidou P, Verweij N, Benjamins JW, Engmann J, Noah TL, Verma A, Slieker RC, Lo KS, Zilhao NR, Kleber ME, Delgado GE, Huo S, Ikeda DD, Iha H, Yang J, Liu J, Demirkan A, Leonard HL, Marten J, Emmel C, Schmidt B, Smyth LJ, Canadas-Garre M, Wang C, Nakatochi M, Wong A, Hutri-Kahonen N, Sim X, Xia R, Huerta-Chagoya A, Fernandez-Lopez JC, Lyssenko V, Nongmaithem SS, Sankareswaran A, Irvin MR, Oldmeadow C, Kim H-N, Ryu S, Timmers PRHJ, Arbeeva L, Dorajoo R, Lange LA, Prasad G, Lores-Motta L, Pauper M, Long J, Li X, Theusch E, Takeuchi F, Spracklen CN, Loukolaet al., 2022, A multi-layer functional genomic analysis to understand noncoding genetic variation in lipids, American Journal of Human Genetics, Vol: 109, Pages: 1366-1387, ISSN: 0002-9297

A major challenge of genome-wide association studies (GWASs) is to translate phenotypic associations into biological insights. Here, we integrate a large GWAS on blood lipids involving 1.6 million individuals from five ancestries with a wide array of functional genomic datasets to discover regulatory mechanisms underlying lipid associations. We first prioritize lipid-associated genes with expression quantitative trait locus (eQTL) colocalizations and then add chromatin interaction data to narrow the search for functional genes. Polygenic enrichment analysis across 697 annotations from a host of tissues and cell types confirms the central role of the liver in lipid levels and highlights the selective enrichment of adipose-specific chromatin marks in high-density lipoprotein cholesterol and triglycerides. Overlapping transcription factor (TF) binding sites with lipid-associated loci identifies TFs relevant in lipid biology. In addition, we present an integrative framework to prioritize causal variants at GWAS loci, producing a comprehensive list of candidate causal genes and variants with multiple layers of functional evidence. We highlight two of the prioritized genes, CREBRF and RRBP1, which show convergent evidence across functional datasets supporting their roles in lipid biology.

• Abstract
• Publisher Web Link
• Author Web Link
• Cite

Lin Q, Ye T, Ye P, Borghi C, Cro S, Damasceno A, Khan N, Nilsson P, Prabhakharan D, Ramirez A, Schlaich M, Schutte A, Stergiou G, Weber M, Beaney T, Poulter Net al., 2022, Hypertension in stroke survivors and associations with national premature stroke mortality: data on 2.5 million participants from multinational screening campaigns., The Lancet Global Health, Vol: 10, Pages: e1141-e1149, ISSN: 2214-109X

BackgroundBlood pressure (BP) control plays a pivotal role in reducing stroke incidence and recurrence. May Measurement Month (MMM) is the largest global BP screening campaign, initiated in 2017 by the International Society of Hypertension (ISH). We aim to compare MMM participants with and without a previous stroke and to investigate associations between national-level estimates of BP management from MMM and premature stroke mortality.MethodsOver 2.5 million volunteers (≥18 years) were screened in May 2017 and 2018 from 92 countries. Three seated BPs and demographic, lifestyle, and cardiovascular disease data were collected. Associations between risk factors and stroke history were analysed using mixed-effects logistic regression. Linear regression was used to investigate associations between national-level estimates of BP management and premature stroke mortality based on Global Burden of Diseases (GBD) data. FindingsOf 2 222 399 (88·4%) participants with recorded data on a history of stroke, 62 639 (2·8%) reported a previous stroke. Those with a stroke history had higher rates of hypertension and treated and controlled hypertension than those without. One third of those with a stroke history had untreated or treated but uncontrolled BP (≥140/90 mmHg). Strong positive associations were found between national premature stroke mortality and increasing mean systolic BP levels and proportion of participants with raised BP and strong negative associations with the proportions of hypertensives on treatment and with controlled BP. InterpretationBP control remains suboptimal worldwide amongst those with a previous stroke. National estimates of BP management reflect national premature stroke mortality sufficiently well to provide a prompt for policymakers to promote BP screening and management.

• Abstract
• Publisher Web Link
• Open Access Link
• Cite

Juraschek SP, Wang D, McEvoy JW, Harrap S, Harris K, Mancia G, Marre M, Neal B, Patel A, Poulter NR, Williams B, Chalmers J, Woodward M, Selvin Eet al., 2022, Effects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCE, International Journal of Cardiology, Vol: 358, Pages: 103-109, ISSN: 0167-5273

OBJECTIVE: Observational data suggest a potential for subclinical cardiac damage from intensive blood glucose or blood pressure (BP) control, particularly in adults with very low blood glucose and BP levels. However, this has not been tested in a randomized trial. METHODS: The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Research Controlled Evaluation (ADVANCE) study was a factorial, randomized trial designed to test the effects of intensive blood glucose (hemoglobin A1c ≤6.5% versus usual care) and intensive BP (combination of perindopril-indapamide versus placebo) control on vascular events in adults with diabetes. Using mixed effects tobit models, we determined the effect of the randomized interventions on change in subclinical cardiac injury (high sensitivity cardiac troponin T [hs-cTnT]) and strain (N-terminal b-type pro natriuretic peptide [NT-proBNP]), 1 year after randomization. RESULTS: Among the 682 participants, mean age was 66.1 (SD, 6.5) years; 40% were women. Mean baseline hemoglobin A1c was 7.4% (SD, 1.5) and systolic/diastolic BP was 147 (SD,21)/81 (SD,11) mmHg. After 1 year, intensive versus standard glucose control did not significantly change hs-cTnT (1.5%; 95%CI:-4.9,8.2) or NT-proBNP (-10.3%; 95%CI: -20.2%,0.9%). Intensive versus standard BP control also did not affect hs-cTnT (-2.9%; 95%CI: -8.9,3.6), but did significantly lower NT-proBNP by 21.6% (95%CI:-30.2%,-11.9%). Changes in systolic BP at 1 year (versus baseline) were strongly associated with NT-proBNP (P = 0.004), but not hs-cTnT (P = 0.95). CONCLUSIONS: In adults with diabetes, intensive BP control reduced NT-proBNP without increasing hs-cTnT, supporting the benefits and safety of intensive BP control in adults with diabetes. This trial is registered at clinicaltrials.gov, number: NCT00145925.

• Abstract
• Author Web Link
• Open Access Link
• Cite